Reviewing Arbutus Biopharma Corporation (ABUS)’s and Innovate Biopharmaceuticals Inc. (NASDAQ:INNT)’s results

Arbutus Biopharma Corporation (NASDAQ:ABUS) and Innovate Biopharmaceuticals Inc. (NASDAQ:INNT), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arbutus Biopharma Corporation 2 0.00 30.95M -2.80 0.00
Innovate Biopharmaceuticals Inc. 1 0.00 24.63M -0.67 0.00

In table 1 we can see Arbutus Biopharma Corporation and Innovate Biopharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Arbutus Biopharma Corporation 1,238,000,000.00% -583.1% -84.7%
Innovate Biopharmaceuticals Inc. 3,690,993,556.12% 0% -194.6%

Analyst Recommendations

In next table is given Arbutus Biopharma Corporation and Innovate Biopharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Arbutus Biopharma Corporation 0 0 1 3.00
Innovate Biopharmaceuticals Inc. 0 0 0 0.00

Arbutus Biopharma Corporation has an average price target of $6, and a 95.44% upside potential.

Institutional & Insider Ownership

The shares of both Arbutus Biopharma Corporation and Innovate Biopharmaceuticals Inc. are owned by institutional investors at 34.4% and 7.4% respectively. Arbutus Biopharma Corporation’s share owned by insiders are 40.87%. Comparatively, Innovate Biopharmaceuticals Inc. has 0.1% of it’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Arbutus Biopharma Corporation 37.13% 57.93% 45.86% 43.12% -50% -40.21%
Innovate Biopharmaceuticals Inc. -6.03% -15.75% -19.45% -41.83% -69.2% -68.27%

For the past year Arbutus Biopharma Corporation has stronger performance than Innovate Biopharmaceuticals Inc.


Arbutus Biopharma Corporation beats on 6 of the 10 factors Innovate Biopharmaceuticals Inc.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. Its late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease (IBD), and nonalcoholic steatohepatitis (NASH). The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease. It is also developing INN-108, which is entering into Phase 2 clinical trials for the treatment of mild to moderate ulcerative colitis. In addition, the company owns the global rights to INN-329, a proprietary formulation of secretin, a peptide hormone used to enhance visualization in magnetic resonance cholangiopancreatography procedures. Innovate Biopharmaceuticals, Inc. was founded in 2012 and is based in Raleigh, North Carolina.